Ishii Y - Search Results

1

Prediction of hepatic clearance in human from in vitro data for successful drug development.

Chiba M, Ishii Y, Sugiyama Y. Chiba M, et al. Among authors: ishii y. AAPS J. 2009 Jun;11(2):262-76. doi: 10.1208/s12248-009-9103-6. Epub 2009 Apr 30. AAPS J. 2009. PMID: 19408130 Free PMC article. Review.

2

A trapping method for semi-quantitative assessment of reactive metabolite formation using [35S]cysteine and [14C]cyanide.

Inoue K, Shibata Y, Takahashi H, Ohe T, Chiba M, Ishii Y. Inoue K, et al. Among authors: ishii y. Drug Metab Pharmacokinet. 2009;24(3):245-54. doi: 10.2133/dmpk.24.245. Drug Metab Pharmacokinet. 2009. PMID: 19571436

3

Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.

Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, Kanatani A, Fukami T, Yamazaki M, Chiba M, Ishii Y. Ohe T, et al. Among authors: ishii y. Drug Metab Dispos. 2003 Oct;31(10):1251-4. doi: 10.1124/dmd.31.10.1251. Drug Metab Dispos. 2003. PMID: 12975334

4

Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.

Shibata Y, Takahashi H, Chiba M, Ishii Y. Shibata Y, et al. Among authors: ishii y. Drug Metab Dispos. 2002 Aug;30(8):892-6. doi: 10.1124/dmd.30.8.892. Drug Metab Dispos. 2002. PMID: 12124306

5

Aromatic substitution reaction of 2-chloropyridines catalyzed by microsomal glutathione S-transferase 1.

Inoue K, Ohe T, Mori K, Sagara T, Ishii Y, Chiba M. Inoue K, et al. Among authors: ishii y. Drug Metab Dispos. 2009 Sep;37(9):1797-800. doi: 10.1124/dmd.109.027698. Epub 2009 Jun 18. Drug Metab Dispos. 2009. PMID: 19541825

6

A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.

Shibata Y, Takahashi H, Chiba M, Ishii Y. Shibata Y, et al. Among authors: ishii y. Drug Metab Pharmacokinet. 2008;23(5):328-39. doi: 10.2133/dmpk.23.328. Drug Metab Pharmacokinet. 2008. PMID: 18974610

7

Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist.

Kobayashi K, Tsujita T, Ito H, Ozaki S, Tani T, Ishii Y, Okuda S, Tadano K, Fukuroda T, Ohta H, Okamoto O. Kobayashi K, et al. Among authors: ishii y. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4729-32. doi: 10.1016/j.bmcl.2009.06.051. Epub 2009 Jun 17. Bioorg Med Chem Lett. 2009. PMID: 19564110

8

A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K+ channel.

Yoshizumi T, Takahashi H, Miyazoe H, Sugimoto Y, Tsujita T, Kato T, Ito H, Kawamoto H, Hirayama M, Ichikawa D, Azuma-Kanoh T, Ozaki S, Shibata Y, Tani T, Chiba M, Ishii Y, Okuda S, Tadano K, Fukuroda T, Okamoto O, Ohta H. Yoshizumi T, et al. Among authors: ishii y. J Med Chem. 2008 Jul 10;51(13):4021-9. doi: 10.1021/jm701590h. Epub 2008 Jun 7. J Med Chem. 2008. PMID: 18537234

9

Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.

Takahashi T, Haga Y, Sakamoto T, Moriya M, Okamoto O, Nonoshita K, Shibata T, Suga T, Takahashi H, Hirohashi T, Sakuraba A, Gomori A, Iwaasa H, Ohe T, Ishihara A, Ishii Y, Kanatani A, Fukami T. Takahashi T, et al. Among authors: ishii y. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3511-6. doi: 10.1016/j.bmcl.2009.05.013. Epub 2009 May 9. Bioorg Med Chem Lett. 2009. PMID: 19464889

10

Potent and orally active ET(A) selective antagonists with 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acid structures.

Yoshizumi T, Takahashi H, Ohtake N, Jona H, Sato Y, Kishino H, Sakamoto T, Ozaki S, Takahashi H, Shibata Y, Ishii Y, Saito M, Okada M, Hayama T, Nishikibe M. Yoshizumi T, et al. Among authors: ishii y. Bioorg Med Chem. 2004 May 1;12(9):2139-50. doi: 10.1016/j.bmc.2004.02.033. Bioorg Med Chem. 2004. PMID: 15080914

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results